NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE113006 Query DataSets for GSE113006
Status Public on Apr 11, 2019
Title Expression data from whole blood of RRMS patients initiating treatment with intramuscular IFN-β1a (Avonex®) obtained exactly 12 hours after treatment.
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Interferon beta (IFN-β) is a first line treatment for patients with relapsing forms of MS, but response to the drug varies and to date there are no biomarkers associated with individual patient response. Whole blood gene expression data from a clinical study of patients initiating treatment with intramuscular IFN-β1a (Avonex®) was comprehensively analyzed for gene signatures distinguishing between good vs. poor responders where the latter were defined by increases in number and size of observed lesions in quantitative imaging over a 6-month period. We observed signatures related to B-cell activation in subject gene expression prior to treatment while T-cell and interleukin signatures were observed in the same subjects immediately after treatment. These signatures form a basis for developing predictors of IFN-β1a response in patients both prior to and after IFN-β1 treatment.
 
Overall design Whole blood was obtained from 85 RRMS/CIS precisely 12 hours after injection of intramuscular IFN-β1a (Avonex®) at an initial (characteristic: time point=T0) and 6-month visit (characteristic: time point=T6). Clinical response was measured by quantifying new and enlarging brain lesions on T2-weighted MRI scans at 6 months (T6) compared to baseline (T0). Based on pre-defined MRI criteria, a group of 15 poor responders (characteristic: response=Poor) with 3 or more new or enlarging lesions was identified, and compared with a group of 15 good responders (characteristic: response=Good) selected from the full patient cohort. The remaining patients (characteristic: response=Indeterminate) were not used for the analysis.
 
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Apr 11, 2018
Last update date Apr 12, 2019
Contact name Mark R Chance
Organization name Case Western Reserve University School of Medicine
Street address 10900 Euclid Ave
City Cleveland
State/province OH
ZIP/Postal code 44106
Country USA
 
Platforms (1)
GPL13158 [HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate
Samples (169)
GSM3093321 7584001_0_Post whole blood draw, T0, Post-injection
GSM3093322 7584001_6_Post whole blood draw, T6, Post-injection
GSM3093323 7584004_0_Post whole blood draw, T0, Post-injection
This SubSeries is part of SuperSeries:
GSE113007 Expression data from whole blood of RRMS patients initiating treatment with intramuscular IFN-β1a (Avonex®)
Relations
BioProject PRJNA449725

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE113006_RAW.tar 321.7 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap